Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label)

NCT01433354 · clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
TERMINATED
Status
119
Enrollment
INDUSTRY
Sponsor class

Stopped The study treatment failed to demonstrate efficacy in target population in two other clinical studies (CAFQ056B2214 and CAFQ056A2212).

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals